Sign In
NASDAQ:AXDX
Accelerate Diagnostics Stock News
$1.58
+0.0100 (+0.637%)
At Close: Dec 06, 2024
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript
11:58pm, Friday, 08'th Nov 2024
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and C
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
06:41pm, Thursday, 07'th Nov 2024
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago.
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results
04:05pm, Thursday, 07'th Nov 2024
TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024.
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
04:30pm, Friday, 25'th Oct 2024
TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m.
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
01:16pm, Tuesday, 01'st Oct 2024
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
09:15am, Monday, 30'th Sep 2024
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from posit
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
11:06am, Wednesday, 14'th Aug 2024
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
06:55pm, Saturday, 10'th Aug 2024
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and CEO
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
06:46pm, Thursday, 08'th Aug 2024
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $2.36 per share a year ago.
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
04:05pm, Thursday, 08'th Aug 2024
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024.
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial
04:00pm, Thursday, 08'th Aug 2024
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results
11:09am, Thursday, 08'th Aug 2024
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m.
Dead Cat Bounce: 3 Stocks to Sell Before They Plunge Again
12:05pm, Thursday, 13'th Jun 2024
A dead cat bounce is when a falling stock sees a short-term recovery, but is ultimately likely to head lower. It comes from the idea that “even a dead cat will bounce if it falls from a great height
Accelerate Diagnostics, Inc. (AXDX) Q1 2024 Earnings Call Transcript
07:50pm, Wednesday, 08'th May 2024
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - Chief Executive Offi
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
07:26pm, Wednesday, 08'th May 2024
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago.
